RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+0.75%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$911M
AUM Growth
+$911M
(-5%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9
Top Buys
| 1 |
UnitedHealth
UNH
|
$17.9M |
| 2 |
McKesson
MCK
|
$8.23M |
| 3 |
Cooper Companies
COO
|
$7.72M |
| 4 |
Abbott
ABT
|
$6.74M |
| 5 |
Cigna
CI
|
$5.72M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$32.2M |
| 2 |
Johnson & Johnson
JNJ
|
$17.7M |
| 3 |
Medtronic
MDT
|
$9.11M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$6.48M |
| 5 |
Pfizer
PFE
|
$6.46M |
Sector Composition
| 1 | Healthcare | 95.19% |
| 2 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$281B
| $35.7M | 3.92% | 76,000 +38,000 | +100% | +$17.9M |
|
2
Boston Scientific
BSX
$156B
| $29.8M | 3.27% | 600,000 +15,000 | +3% | +$744K |
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $28.8M | 3.16% | 35,500 -1,500 | -4% | -$1.22M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $26.1M | 2.86% | 83,500 +3,500 | +4% | +$1.09M |
|
5
Elevance Health
ELV
$71.8B
| $25.7M | 2.82% | 56,000 +11,000 | +24% | +$5.05M |
|
6
Merck
MRK
$210B
| $25.5M | 2.8% | 241,000 +26,000 | +12% | +$2.75M |
|
7
Becton Dickinson
BDX
$55.3B
| $25M | 2.75% | 102,000 +19,000 | +23% | +$4.66M |
|
|
8
Cooper Companies
COO
$13.4B
| $25M | 2.74% | 68,000 +21,000 | +45% | +$7.72M |
|
9
AbbVie
ABBV
$372B
| $24M | 2.64% | 152,000 +22,000 | +17% | +$3.47M |
|
10
Cencora
COR
$56.5B
| $23.7M | 2.61% | 149,000 -24,000 | -14% | -$3.82M |
|
11
Tenet Healthcare
THC
$16.3B
| $23.6M | 2.59% | 410,000 -60,750 | -13% | -$3.5M |
|
12
Thermo Fisher Scientific
TMO
$186B
| $23.1M | 2.53% | 41,000 +1,000 | +3% | +$563K |
|
|
13
McKesson
MCK
$85.4B
| $22.2M | 2.44% | 62,000 +23,000 | +59% | +$8.23M |
|
14
HCA Healthcare
HCA
$94.5B
| $21.8M | 2.39% | 84,000 -6,000 | -7% | -$1.56M |
|
15
Jazz Pharmaceuticals
JAZZ
$7.75B
| $21.7M | 2.39% | 150,000 +22,000 | +17% | +$3.19M |
|
|
16
Cigna
CI
$80.3B
| $21.5M | 2.36% | 84,500 +22,500 | +36% | +$5.72M |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $21.4M | 2.35% | 225,000 -29,000 | -11% | -$2.76M |
|
18
Gilead Sciences
GILD
$140B
| $21.1M | 2.32% | 259,000 -11,000 | -4% | -$896K |
|
|
19
Medtronic
MDT
$119B
| $18.6M | 2.04% | 235,000 -115,000 | -33% | -$9.11M |
|
|
20
Abbott
ABT
$231B
| $18.3M | 2.01% | 185,000 +68,000 | +58% | +$6.74M |
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $14.8M | 1.63% | 76,000 +3,000 | +4% | +$585K |
|
|
AXNX
22
DELISTED
Axonics, Inc. Common Stock
AXNX
| $14.7M | 1.62% | 271,062 +41,062 | +18% | +$2.23M |
|
23
Humana
HUM
$36.5B
| $14.7M | 1.61% | 30,000 -9,000 | -23% | -$4.4M |
|
|
SWAV
24
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $14.3M | 1.58% | 67,000 +20,000 | +43% | +$4.28M |
|
25
Biogen
BIIB
$19.4B
| $13.1M | 1.43% | 47,500 +17,500 | +58% | +$4.81M |
|